IOL Chemicals & Pharmaceuticals share price today

IOL Chemicals & Pharmaceuticals Ltd's share price was ₹183.77 at the close on 4 November 2026. It has been rising for 25 weeks. That is 26.5% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 38 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today IOL Chemicals & Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹69 and ₹209, and at that close it sat 82% of the way up from that low.

Over the last 11 years the share price moved +1,213% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 8 quarters in a row, highest quarterly profit in 14 quarters and highest quarterly revenue in 16 quarters.

1. Revenue up on a year earlier for 8 quarters in a row

   In the September 2026 quarter revenue was ₹795 crore, +40% on a year earlier.

2. Highest quarterly profit in 14 quarters

   Profit of ₹65 crore in the September 2026 quarter is the highest of the last 14 quarters.

3. Highest quarterly revenue in 16 quarters

   Revenue of ₹795 crore in the September 2026 quarter is the highest of the last 16 quarters.

For July to September 2026 (the quarter ended 30 September 2026), IOL Chemicals & Pharmaceuticals reported revenue of ₹795 crore, up 40.0% from ₹568 crore a year earlier, and a profit of ₹65.0 crore, up 116.7% from ₹30.0 crore.

IOL Chemicals & Pharmaceuticals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 29 September 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

IOL Chemicals & Pharmaceuticals closed at ₹183.77 on 4 November 2026, up 102.7% from ₹90.66 a year earlier (7 November 2025) and up 66.2% over five years. Its highest weekly close since March 2016 was ₹209.45 on 1 October 2026.

IOL Chemicals & Pharmaceuticals share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: IOL Chemicals & Pharmaceuticals closed at ₹183.77, up 3.4% on the week and down 12.3% on the month. Results for July to September 2026: Revenue up 40.0% and profit up 116.7% on a year earlier.

Earlier

• 29 Sep 2026: IOL Chemicals & Pharmaceuticals held its results call for April to June 2026. Management guided: Ibuprofen capacity: additional 6,000 MTPA to 18,000 MTPA, commissioning by December 2027.
• 17 Feb 2026: ex-date for an interim dividend of ₹1 a share.
• 11 Mar 2025: Share split: face value cut from ₹10 to ₹2 a share (ex-date).

IOL Chemicals & Pharmaceuticals paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.54% at the ₹183.77 close on 4 November 2026. The last was an interim dividend of ₹1 a share, ex-date 17 February 2026.

IOL Chemicals & Pharmaceuticals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. IOL Chemicals & Pharmaceuticals Ltd paid out 21% of its profit as dividends in FY26, and it paid a dividend in each of its last 5 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 29 September 2026, IOL Chemicals & Pharmaceuticals' management guided: Ibuprofen capacity: additional 6,000 MTPA to 18,000 MTPA, commissioning by December 2027.

“These initiatives are expected to provide approximately 25-30% incremental revenue potential over the coming years once the projects become fully operational, and they are all being funded through internal accruals.”Abhay Raj Singh, on the call for April to June 2026

What management guided

• Formulations CDMO: 1,500 million tablets annually or equivalent direct compressible grade; commercialization in October to December 2026.
• Three initiatives: approximately ₹500 crore of spending and 25-30% incremental revenue once fully operational, funded through internal accruals.
• Non-Ibuprofen APIs to reach around 50% of pharma revenue; expanded API capacity expected fully utilized in FY28-FY29.
• CDMO optimal utilization expected by next financial year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 29 September 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

The changes showing up in IOL Chemicals & Pharmaceuticals' own numbers are costs spread over more sales. It is too early to say whether they last.

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Checked against results and calls up to April to June 2026, 10 October 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

The non-ibuprofen share stalls near 40% of pharma revenue or export share drops back below 25%.

Each change stops working if

• Non-ibuprofen API mix and regulated exports: The non-ibuprofen share stalls near 40% of pharma revenue or export share drops back below 25%.
• New customer-led capacity: ibuprofen expansion, tablet contract manufacturing, tolling: No commercial contract-manufacturing batch by the March 2027 quarter, or the ibuprofen expansion is commissioned without named customer volumes.
• Ibuprofen volume back after destocking: Ibuprofen utilization drops below 85% or prices fall back while input costs stay high.
• Chemicals: ethyl acetate spread and triacetin: Ethyl acetate spread returns to the $110-120 per ton historical band.

The main risks

• June 2026 quarter may be partly a dispatch pull-forward: Annualized June-quarter revenue of about ₹3,024 crore is above the top of the FY27 guided range (about ₹2,783 crore), and management declined to upgrade. ⚠ estimate
• Chemical spread reverting: Ethyl acetate spreads of $150-160 per ton are above the $110-120 historical band. ✓ fact
• Free cash flow stays thin while the new capital spending is built: Five-year capital spending of ₹994 crore was 111% of operating cash flow; another ₹495-500 crore plus ₹200-250 crore a year is planned. ✓ fact
• Ownership data is a year old in our database: Our shareholding rows stop at June 2025, so recent promoter, FII and DII moves cannot be checked. ⚠ estimate

Our read after the April to June 2026 results, written 10 October 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When IOL Chemicals & Pharmaceuticals reports October to December 2026, these are the 5 checks that show whether the story is still on course. First: Operating margin stays above 13% in the September 2026 quarter while paracetamol utilisation moves above 60% and management does not report ethyl acetate spreads falling back toward $110 to 120 a ton.

IOL Chemicals & Pharmaceuticals is on 2 of our India lists: Multibagger study list and Pharma stocks.

IOL Chemicals & Pharmaceuticals Ltd earned ₹65.0 Cr of net profit in the Sep 2026 quarter, +116.7% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹138 Cr. Over 4 years profit has grown −4.8% a year on average. That is 8.2% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹30.0 Cr.

For the full year, FY26 profit was ₹138 Cr (+36.6% on the year before).

Why profit moved: revenue changed +40.0% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +69.0% and revenue +26.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY27-Q1. revenue ₹756 Cr and profit ₹64 Cr as reported.

FY27-Q2. revenue ₹795 Cr and profit ₹65 Cr as reported.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

IOL Chemicals & Pharmaceuticals Ltd reported ₹795 Cr of revenue in the Sep 2026 quarter, +40.0% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 4 years it has grown 1.5% a year on average. The last full year, FY26, came in at ₹2,319 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Non-ibuprofen revenue grew 67% year on year in the June 2026 quarter across paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate and levetiracetam. This reduces dependence on one molecule that went through a 3-4 quarter destocking slump. Exports to regulated markets carry higher realizations; Management goals about half of pharma revenue from non-ibuprofen products over the near-to-medium term.

The last four reported quarters add to ₹2,750 Cr.

FY26 revenue was ₹2,319 Cr, +11.5% on the year before.

Recent pace: the last four quarters grew +26.3% on average, against 1.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +26.7%, against +15.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +75.0%, against +42.5% a year (accelerating).

FY27-Q1. revenue ₹756 Cr and profit ₹64 Cr as reported.

FY27-Q2. revenue ₹795 Cr and profit ₹65 Cr as reported.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

IOL Chemicals & Pharmaceuticals Ltd's operating margin was 14.0% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 10.0% and 12.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. This is the operating-leverage pattern from our model library: the costs are already installed, so incremental tonnes drop largely to operating profit. The June 2026 quarter showed it in the numbers: revenue rose 22% over March 2026 while gross margin fell about 3 points, yet operating margin held near 13.7%, because fixed costs were spread over more sales. Paracetamol is the main unused asset; management guides about 70% use by year-end FY27 and 100% in FY28, but the same plant missed its earlier March 2026 goal of 65%.

Why the margin moved: operating margin changed +3.7 percentage points on the year while gross margin changed +1.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

FY27-Q1. revenue ₹756 Cr and profit ₹64 Cr as reported.

FY27-Q2. revenue ₹795 Cr and profit ₹65 Cr as reported.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Over the last 3 years, 183% of IOL Chemicals & Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹214 Cr of operating cash against ₹138 Cr of profit. After ₹165 Cr of spending on assets, ₹49.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 183% of profit came in as cash: the cash cycle got 11 days shorter between FY22 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 3.0× depreciation over three years. The next section checks what that spending is building.

IOL Chemicals & Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 68 days in FY26, down from 79 days in FY22. It spent ₹651 Cr on assets over the last 3 years. Customers take 95 days to pay, and stock sits for 91 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. The tablet line (1,500 million tablets a year) is EU-GMP certified and about Rs 115 crore of cost is mostly spent; anchor customers are still approving dossiers. Ibuprofen goes from 12,000 to 18,000 MTPA by December 2027. Roughly 30% of the Rs 495 crore was complete by September 2026. Management expects about 15% company ROCE once everything runs, versus 11% in FY26. The figures given on calls are not consistent: the tablet line's asset turn was stated as 1-1.25x and then as about 2.5x three weeks later.

At FY26 sales of ₹2,319 Cr, each day of that cycle ties up about ₹6.4 Cr, so roughly ₹432 Cr is tied up in the business at any time.

FY26: customers took 95 days to pay and stock sat for 91 days, about 3.0 months of sales sitting as stock, for a full cycle of 68 days, shorter than FY22's 79.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 91 days. Customers pay about 95 days after that. Suppliers are paid at 118 days. Together that makes the 68-day cycle.

Spending on assets: ₹651 Cr over the last 3 years, against ₹215 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹96.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

IOL Chemicals & Pharmaceuticals Ltd's P/E is 25.4×, near the high end of its own history: higher than 79% of past readings. Its usual P/E (the middle reading) is 18.7×, over 4.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹6.92.